Inhalers for chronic obstructive pulmonary disease (COPD) are a mainstay of treatment. These medications are inhaled through ...

Respiratory Inhaler Devices MarketThe global respiratory inhaler devices market, valued at USD 37,258.5 million in 2023, is projected to grow at a compound annual growth rate (CAGR) of 4.90%, reaching ...

Poor treatment of asthma and COPD puts a huge burden on the NHS. For example, £1 billion is spent on asthma treatment in the UK each year and represents 60,000 to 65,000 hospital admissions. In ...

Many people with COPD can control their symptoms by using inhaled medicines each day. But inhaled medicines may not offer enough relief for people who also have high levels of a type of white ...

Purpose. Special considerations in the selection of medication inhaler devices for elderly patients with chronic obstructive pulmonary disease (COPD) in the ambulatory care setting are reviewed.

Chronic obstructive pulmonary disease is a serious, progressive illness that hits the homeless and underinsured the hardest.

Patients with COPD often experience chronic cough, difficulty breathing, and reduced lung function. While the respiratory disease is not curable, it can be treated and managed with medications ...

Currently, COPD-marketed therapy leaders include GSK’s Trelegy Ellipta, which is set to grow in sales to $2.16bn by 2033.

AIIMS has reported a increase in cases related to respiratory issues, particularly asthma and COPD allegedly due to Delhi air ...

Early fall is when asthma flare-ups peak in the U.S., and a warming climate is bad news for sufferers: It means more ground-level ozone, a longer pollen season and more wildfire smoke – -all ...